SCHEMBL37830

SCHEMBL37830

O=C(O)CCCCCNc1ccc([N+](=O)[O-])cc1[N+](=O)[O-]

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.63
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 3/20 0.62
POLB P06746 2/20 0.60
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
GAA P10253 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
HCAR3 P49019 3/20 0.55
PRSS1 P07477 3/20 0.54
PKM P14618 1/20 0.54
HPGD P15428 2/20 0.52
THRB P10828 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
NPC1 O15118 1/20 0.50
TRPA1 O75762 1/20 0.50
CYP2C9 P11712 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295085 1.00 MAPT (0.63) MAPTKDM4EALDH1A1POLBKMT2A
SCHEMBL29928397 1.00 MAPT (0.63) MAPTKDM4EALDH1A1POLBKMT2A
SCHEMBL9755054 0.99 MAPT (0.65) MAPTKDM4EALDH1A1POLBKMT2A
SCHEMBL4301793 0.95 MAPT (0.70) MAPTKDM4EALDH1A1POLBKMT2A
SCHEMBL10932609 0.90 MAPT (0.63) MAPTKDM4EALDH1A1POLBKMT2A
SCHEMBL7349997 0.89 MAPT (0.62) MAPTKDM4EALDH1A1POLBKMT2A
SCHEMBL17875231 0.88 MAPT (0.56) MAPTKDM4EALDH1A1POLBKMT2A
SCHEMBL27343040 0.86 MAPT (0.73) MAPTKDM4EALDH1A1POLBGAA
SCHEMBL8536167 0.86 PRSS1 (0.56) MAPTKDM4EALDH1A1POLBKMT2A
SCHEMBL14364287 0.85 MAPT (0.60) MAPTKDM4EALDH1A1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7881871-B2 Method for designing surfaces BIO-LAYER PTY LIMITED (AU) 2011-02-01 US claimed
EP-1700244-A4 A METHOD FOR DESIGNING SURFACES BIO LAYER PTY LTD (AU) 2009-07-08 EP claimed
US-20070099235-A1 Method for designing surfaces BIO-LAYER PTY LIMITED (AU) 2007-05-03 US claimed
EP-1700244-A1 A METHOD FOR DESIGNING SURFACES Bio-Layer Pty Limited (AU) 2006-09-13 EP claimed
WO-2005057462-A1 A METHOD FOR DESIGNING SURFACES BIO-LAYER PTY LIMITED (AU) 2005-06-23 WO claimed
WO-2025129193-A1 GLYCOSYLTRANSFERASES AND RELATED METHODS NEW ENGLAND BIOLABS, INC. (US) 2025-06-19 WO disclosed
EP-3382039-B1 METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS BIOCEPT INC (US) 2023-09-13 EP disclosed
US-20230022745-A1 Methods for Labeling a Population of RNA Molecules NEW ENGLAND BIOLABS, INC. (US) 2023-01-26 US disclosed
US-20220389478-A1 METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR ORYZON GENOMICS SA (ES) 2022-12-08 US disclosed
US-11479766-B2 Methods for labeling a population of RNA molecules NEW ENGLAND BIOLABS, INC. (US) 2022-10-25 US disclosed
US-20220017957-A1 METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS AEGEA BIOTECHNOLOGIES, INC. 2022-01-20 US disclosed
US-11034991-B2 Methods to determine KDM1A target engagement and chemoprobes useful therefor ORYZON GENOMICS S.A. (ES) 2021-06-15 US disclosed
US-4366243-A POLYVINYL ALCOHOL, ALBUMIN MILES LABORATORIES, INC. (US) 1982-12-28 US disclosed
US-4340668-A Heme-labeled specific binding assay MILES LABORATORIES, INC. (US) 1982-07-20 US disclosed
EP-0051213-A1 Homogeneous specific binding assay device, method for preparing it and analytical method using the device MILES LABORATORIES, INC. (US) 1982-05-12 EP disclosed
US-4318982-A FMN-Labeled specific binding assay MILES LABORATORIES, INC. (US) 1982-03-09 US disclosed
US-4318983-A Fad-labeled specific binding assay monitored with apoglutathione reductase or apolipoamide dehydrogenase MILES LABORATORIES, INC. (US) 1982-03-09 US disclosed
US-4255566-A N6-(OMEGA-AMINOALKYL)ADENINE DINUCLEOTIDE DERIVATIVES; IMMUNOASSAY MILES LABORATORIES (US) 1981-03-10 US disclosed
US-4238565-A Specific binding assay with a prosthetic group as a label component MILES LABORATORIES, INC. (US) 1980-12-09 US disclosed
US-4134792-A Specific binding assay with an enzyme modulator as a labeling substance MILES LABORATORIES, INC. (US) 1979-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389478-A1 METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR KDM1B, KDM1A, KDM7A MAPT 4545/4885KDM4E 22/4885ALDH1A1 1155/4885
US-11479766-B2 Methods for labeling a population of RNA molecules RNGTT, RNMT, MTAP MAPT 4076/4885KDM4E 1517/4885ALDH1A1 2357/4885
US-20230022745-A1 Methods for Labeling a Population of RNA Molecules RNGTT, RNMT, MTAP MAPT 4076/4885KDM4E 1517/4885ALDH1A1 2357/4885
US-11034991-B2 Methods to determine KDM1A target engagement and chemoprobes useful therefor KDM1B, KDM1A, KDM7A MAPT 4545/4885KDM4E 22/4885ALDH1A1 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.